Immunoprecise Antibodies Ltd reports results for the quarter ended in January - Earnings Summary

Mindwalk Holdings

16/03/2023 13:32

* Immunoprecise Antibodies Ltd  IPA.OQ  reported a quarterly
adjusted loss of 19 cents​​ per share for the quarter ended in
January. The mean expectation of two analysts for the quarter
was for a loss of 23 cents per share.
    * Revenue rose 7.4% to C$5.17 million from a year ago;
analysts
expected C$5.43 million. 
    * Immunoprecise Antibodies Ltd's reported EPS for the
quarter was
a loss of 19 cents​.
    * The mean earnings estimate of analysts had fallen by
about 76.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Immunoprecise Antibodies Ltd shares had fallen by 28.0%
this
quarter.
    * The company reported a quarterly loss of C$4.7 million.
    * Wall Street's median 12-month price target for
Immunoprecise
Antibodies Ltd is $10.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 16 at 01:31 p.m. UTC. ​All figures in Canadian dollars
unless otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jan. 31 2023      -0.23          -0.19          Beat
 Oct. 31 2022      -0.19          -0.30          Missed